Advertisement
U.S. markets close in 3 hours 52 minutes
Advertisement

Marvel Biosciences Corp. (MBCOF)

Other OTC - Other OTC Delayed Price. Currency in USD
0.08220.0000 (0.00%)
As of 12:05PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
Previous Close0.0822
Open0.0822
BidN/A x N/A
AskN/A x N/A
Day's Range0.0822 - 0.0822
52 Week Range0.0377 - 0.0849
Volume265
Avg. Volume1,299
Market Cap3.272M
Beta (5Y Monthly)0.18
PE Ratio (TTM)N/A
EPS (TTM)-0.0400
Earnings DateDec 15, 2023 - Dec 19, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for MBCOF

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • MARVEL BIOSCIENCES CORP
    Analyst Report: Medtronic plcOne of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for roughly 50% of the company's total sales.
    Rating
    Fair Value
    Economic Moat
    7 days agoMorningstar
View more
  • Newsfile

    Marvel Biosciences Invited to Test MB-204 on Autism by French University

    Calgary, Alberta--(Newsfile Corp. - November 16, 2023) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce a collaboration with Dr. Julie Le Merrer and Dr. Jerome Becker at iBrain Institute, Tours, France to study the effects of MB-204 in mouse models of autism."We are very pleased to have the opportunity to collaborate with Dr. Le Merrer and Dr. ...

  • Newsfile

    Marvel Announces Successful Completion of Toxicology Study in Preparation for Phase 1 Human Trials

    Calgary, Alberta--(Newsfile Corp. - August 22, 2023) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce that it has successfully completed its 4-week good laboratory practice (GLP), FDA investigational new drug (IND), dose-ranging dog and rat studies for its lead drug candidate MB-204 paving the way for Phase 1 human trials to begin. "We are very pleased to ...

  • Newsfile

    Marvel Highlights Key Asset at the 2023 Alzheimer's Association International Conference

    Calgary, Alberta--(Newsfile Corp. - July 10, 2023) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce that it has been selected to present the Company's scientific advancement of its key asset MB-204 titled MB-204: A Novel Adenosine A2a Antagonist for AD, ADHD and Depression at the Alzheimer's Association International Conference (AAIC) Sunday, July 16, 2023: 7:00 AM – 11:55 ...